Paffenholz Pia, Nestler Tim, Maatoug Yasmine, von Brandenstein Melanie, Köditz Barbara, Pfister David, Heidenreich Axel
Klinik für Urologie, Uro-Onkologie, spezielle urologische und roboter-assistierte Chirurgie, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
Department of Urology, Federal Armed Services Hospital Koblenz, Koblenz, Deutschland.
Urologe A. 2021 Mar;60(3):337-343. doi: 10.1007/s00120-020-01432-1. Epub 2021 Jan 11.
The prognostic classification system of the International Germ Cell Cancer Cooperative Group (IGCCCG) for testicular germ cell tumors is based on the histological subtype, location of the primary tumor, extent of metastatic spread and prechemotherapy tumor marker serum concentrations.
In this study, we aim to identify whether the use of preorchiectomy instead of prechemotherapy tumor marker serum concentration has an impact on IGCCCG risk group assignment.
We performed a retrospective analysis including 135 patients with metastasized testicular germ cell tumors. Analysis of the clinical information with a focus on the tumor marker serum concentration preorchiectomy and prechemotherapy was performed, thus leading to the grouping of patients according to IGCCCG risk group assignment.
Using preorchiectomy instead of prechemotherapy tumor markers led to an incorrect IGCCCG risk group classification in 8% (11/135) of all patients, and consequently to a non-guideline concordant treatment. Up-staging was observed in 8 of 11 patients, representing 6% (8/135) of the total patient cohort. Three of the 11 misclassified patients showed a down-staging and thus describe 2% (3/135) of the total patient cohort.
Using preorchiectomy tumor markers instead of prechemotherapy serum concentration might lead to an incorrect IGCCCG risk group assignment as well as non-guideline concordant treatment. Consequently, prechemotherapy tumor marker serum concentration should be applied for guideline concordant staging of patients.
国际生殖细胞癌协作组(IGCCCG)的睾丸生殖细胞肿瘤预后分类系统是基于组织学亚型、原发肿瘤位置、转移扩散范围和化疗前肿瘤标志物血清浓度。
在本研究中,我们旨在确定使用睾丸切除术前而非化疗前肿瘤标志物血清浓度是否会对IGCCCG风险组分配产生影响。
我们进行了一项回顾性分析,纳入了135例转移性睾丸生殖细胞肿瘤患者。重点分析了睾丸切除术前和化疗前的肿瘤标志物血清浓度临床信息,从而根据IGCCCG风险组分配对患者进行分组。
使用睾丸切除术前肿瘤标志物而非化疗前肿瘤标志物导致8%(11/135)的患者IGCCCG风险组分类错误,进而导致不符合指南的治疗。11例患者中有8例出现分期上调,占总患者队列的6%(8/135)。11例分类错误的患者中有3例出现分期下调,占总患者队列的2%(3/135)。
使用睾丸切除术前肿瘤标志物而非化疗前血清浓度可能导致IGCCCG风险组分配错误以及不符合指南的治疗。因此,化疗前肿瘤标志物血清浓度应用于患者的指南一致性分期。